Results 151 to 160 of about 4,114,474 (307)

Viral heart disease

Kardiologia Polska, 2016
Agnieszka, Pawlak, Katarzyna Elżbieta, Gil, Robert Julian, Gil   +2 more
openaire   +2 more sources

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Viral hepatitis surveillance United States, 2013 [PDF]

As part of the Centers for Disease Control and Prevention\ue2\u20ac\u2122s (CDC) National Notifiable Diseases Surveillance System (NNDSS), viral hepatitis case-reports are received electronically from state and territorial health departments via CDC\ue2 ...

core  

2020 National viral hepatitis progress report [PDF]

The National Viral Hepatitis Progress Report provides information on ten data indicators, providing an objective way to assess progress toward achieving key viral hepatitis goals.Publication date from document properties.NationalProgressReport2020 ...

core  

Research Progress, Application, and Industrialization Prospects of Circular RNA Vaccines in Viral Diseases. [PDF]

Vaccines (Basel)
Cai D, Li X, Wang R, Lin C, Wen J, Tian B.   +5 more
europepmc   +1 more source

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

Arthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K. de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P. Denton, Madelon C. Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

2021 National viral hepatitis progress report [PDF]

The National Viral Hepatitis Progress Report provides information on ten data indicators, providing an objective way to assess progress toward achieving key viral hepatitis goals.Publication date from document properties.FactSheet ...

core  

MicroRNAs in veterinary viral diseases: A comprehensive review from molecular mechanisms to clinical translation. [PDF]

Virus Res
Choobineh MR, Choobineh D, Hajieghrari B.   +2 more
europepmc   +1 more source

The Development of Rheumatoid Arthritis–Specific Ambulatory Care–Sensitive Conditions: Results of a Consensus Process

Arthritis Care &Research, EarlyView.
Objective Ambulatory care–sensitive conditions (ACSCs) serve as indicators of access, quality, and performance of the health system. This study aimed to determine rheumatoid arthritis (RA)‐specific ACSCs for use in the evaluation of care system access and quality.
Kara Irwin, Candace H. Feldman, Claire E. H. Barber, Gabriel Fabreau, Jake Jennings, Scott Patten, Cheryl Barnabe, Inflammatory Arthritis‐Specific ACSC Consensus Process Working Group   +7 more
wiley   +1 more source

The Role of Wildlife and Climate Change in the Emergence of One Health-Related Viral Diseases in Australia. [PDF]

Viruses
Ali MW, Hosen ME, Rahaman MM, Kinobe R, Jelocnik M, Sarker S.   +5 more
europepmc   +1 more source